Prolia, a treatment designed for women with postmenopausal osteoporosis who face a high risk of fracture, has long been recognized as a clinically validated option for strengthening and protecting bone density. Its efficacy is supported by a rigorous three-year clinical study involving more than 7,700 women between the ages of 60 and 90 — one of the largest and most comprehensive trials in its category. Roughly half of the participants received Prolia injections, while the remaining group was administered a placebo, allowing researchers to precisely isolate treatment outcomes and long-term safety indicators. The results demonstrated Prolia’s ability to reduce fracture risk, increase bone strength, and help safeguard patients from complications associated with osteoporosis and hypercalcemia, reinforcing its place as a trusted therapeutic option within the postmenopausal community.

My role in the creative development of Prolia-related initiatives required navigating the deep intersection of science, storytelling, and brand integrity. I managed stakeholders from initial concept through full execution, aligning scientific rigor with consumer clarity — a balance essential in pharmaceutical communications, where every word, ratio, and visual gesture must meet strict regulatory standards while still connecting meaningfully with patients and caregivers. This meant working fluidly across internal teams, medical-legal reviewers, cross-disciplinary creatives, and external vendors to ensure accuracy, empathy, and cohesion throughout the entire campaign.

As a senior creative leader, I provided hands-on direction and professional development to the creative staff, shaping not only the work but the people behind it. I mentored designers, writers, and digital artists through complex regulatory constraints, helping them refine their strategic instincts, strengthen their craft, and elevate their conceptual thinking. Under my leadership, the work maintained a consistent brand identity across every channel — print, digital, CRM, social, HCP messaging, and DTC initiatives — ensuring that no matter where a patient encountered Prolia, the experience felt unified, trustworthy, and aligned with the brand’s mission.

I also played a critical role in the evaluation of digital creative concepts, reviewing copy and art direction at key checkpoints prior to internal account reviews. This allowed me to course-correct early, sharpen the storytelling, and advocate for patient-centered clarity — all while maintaining compliance with FDA guidance and industry best practices. In pharma, nuance is everything: What we include, what we simplify, what we emphasize, and what we withhold directly shapes how patients understand their treatment options. I approached each review with that responsibility in mind.

Together, these efforts ensured that the Prolia brand experience remained consistent, strategic, and anchored in both scientific credibility and human impact — ultimately helping to empower women navigating the challenges of osteoporosis with information they could trust.